MILWAUKEE, Sept. 16, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Alder (ALDR) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Alder to H. Lundbeck.
Click here to learn how to join the action: http://ademilaw.com/case/alder-biopharmaceuticals or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Ademi & O'Reilly, LLP alleges Alder's financial outlook is improving and yet shareholders will receive the equivalent of only up to $20 per share for each share of Alder common stock. H. Lundbeck is acquiring Alder at a substantial discount. The merger agreement unreasonably limits competing bids for Alder by prohibiting solicitation of further bids, and imposing a termination penalty if Alder accepts a superior bid. Alder insiders will receive millions of dollars as part of change of control arrangements. We are investigating on the conduct of Alder's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Alder.
If you own common stock in Alder and wish to obtain additional information, please contact Guri Ademi either at email@example.com or toll-free: 866-264-3995, or http://ademilaw.com/case/alder-biopharmaceuticals.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Ademi & O'Reilly, LLP
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content:http://www.prnewswire.com/news-releases/shareholder-alert-ademi--oreilly-llp-investigates-whether-alder-biopharmaceuticals-has-obtained-a-fair-price-in-its-sale-to-h-lundbeck-as-300918689.html